Gene products of chromosome 11q and their association with CCND1gene amplification and tamoxifen resistance in premenopausal breast cancer

Introduction The amplification event occurring at chromosome locus 11q13, reported in several different cancers, includes a number of potential oncogenes. We have previously reported amplification of one such oncogene, namely CCND1, to be correlated with an adverse effect of tamoxifen in premenopaus...
Ausführliche Beschreibung

Introduction The amplification event occurring at chromosome locus 11q13, reported in several different cancers, includes a number of potential oncogenes. We have previously reported amplification of one such oncogene, namely CCND1, to be correlated with an adverse effect of tamoxifen in premenopausal breast cancer patients. Over-expression of cyclin $ D_{1} $ protein, however, confers tamoxifen resistance but not a tamoxifen-induced adverse effect. Potentially, co-amplification of an additional 11q13 gene, with a resulting protein over-expression, is required to cause an agonistic effect. Moreover, during 11q13 amplification a deletion of the distal 11q region has been described. In order to assess the potential impact of the deletion we examined a selected marker for this event. Method Array comparative genomic hybridization analysis was employed to identify and confirm changes in the gene expression of a number of different genes mapping to the 11q chromosomal region, associated with CCND1 amplification. The subsequent protein expression of these candidate genes was then examined in a clinical material of 500 primary breast cancers from premenopausal patients who were randomly assigned to either tamoxifen or no adjuvant treatment. The protein expression was also compared with gene expression data in a subset of 56 breast cancer samples. Results Cortactin and FADD (Fas-associated death domain) over-expression was linked to CCND1 amplification, determined by fluorescence in situ hybridization, but was not associated with a diminished effect of tamoxifen. However, deletion of distal chromosome 11q, defined as downregulation of the marker Chk1 (checkpoint kinase 1), was associated with an impaired tamoxifen response, and interestingly with low proliferative breast cancer of low grade. For Pak1 (p21-activated kinase 1) and cyclin $ D_{1} $ the protein expression corresponded to the gene expression data. Conclusions The results indicate that many 11q13 associated gene products are over-expressed in conjunction with cyclin $ D_{1} $ but not linked to an agonistic effect of tamoxifen. Finally, the deletion of distal 11q, linked to 11q13 amplification, might be an important event affecting breast cancer outcome and tamoxifen response. Ausführliche Beschreibung

Autor*in:	Lundgren, Katja [verfasserIn] Holm, Karolina Nordenskjöld, Bo Borg, Åke Landberg, Göran

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2008

Schlagwörter:	Tamoxifen Comparative Genomic Hybridization Tamoxifen Resistance Comparative Genomic Hybridization Analysis CCND1 Amplification

Anmerkung:	© Lundgren et al.; licensee BioMed Central Ltd. 2008. This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (

Übergeordnetes Werk:	Enthalten in: Breast cancer research - London : BioMed Central, 1999, 10(2008), 5 vom: 29. Sept.
Übergeordnetes Werk:	volume:10 ; year:2008 ; number:5 ; day:29 ; month:09

Links:	Volltext

DOI / URN:	10.1186/bcr2150

Katalog-ID:	SPR029933668